For a hedged play on Incyte (INCY) MarketIntelligenceCenter.com’s patented trade-picking algorithms selected a May 18, 2018 $82.50 covered call for a net debit in the $75.65 area. That is also the break-even stock price for the covered call. …
Incyte has gapped open sharply lower this morning and is now down 18.37 at $64.69 on strong volume. The stock has tumbled to a new low for the year.
The stock’s 52-week high is $20.47. Volume totaled nearly 14 million, about 20 times the daily average. The company’s future is getting a close look after this morning’s failed trial announcement from Incyte. The Williams Companies Inc. …
The biotech sector was on a bumpy ride over the week as shares of Spectrum surged on positive data from a phase II study, while that of Incyte plunged on the failure of melanoma study. In an effort to bolster its presence in the gene …
10 stocks we like better than Incyte When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* David and …
Incyte’s new immunotherapy drug epacadostat failed to work ... The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection. RDInvesting has not been compensated; …
WRCB1mon
Incyte Corp. (NASDAQ: INCY) said on Friday that its experimental drug epacadostat failed to improve the efficiency of Merck & Co’s (NYSE: MRK) Keytruda immunotherapy treatment when the two were used together by newly diagnosed …
Incyte gapped open sharply lower Friday, but traded in a range for the bulk of the session. The stock closed down by 19.05 at $64.02 on the highest volume of the year. Incyte plunged to a new low for the year.